Study Complete
Sponsor ID
20110217
A Randomized, Single-Blind, Single-Dose, 3-Arm, Parallel-Group Study to Determine the Pharmacokinetic Equivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Subjects
Study Details
Protocol Summary
Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available
Study Documents
Study Synopsis
Available Language(s): English
Locations
No locations found.